PDGFRA and hepatocellular carcinoma: The aforementioned data have substantiated, both at the cellular level and using a murine subcutaneous xenograft model, the role of PDGFRA in conferring resistance to lenvatinib in HCC cells, and the capacity of avapritinib to enhance their sensitivity to this drug.